DOM-CIPROFLOXACIN TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Disponible depuis:

DOMINION PHARMACAL

Code ATC:

J01MA02

DCI (Dénomination commune internationale):

CIPROFLOXACIN

Dosage:

100MG

forme pharmaceutique:

TABLET

Composition:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 100MG

Mode d'administration:

ORAL

Unités en paquet:

100

Type d'ordonnance:

Prescription

Domaine thérapeutique:

QUINOLONES

Descriptif du produit:

Active ingredient group (AIG) number: 0123207005; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2004-03-24

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DOM-CIPROFLOXACIN
(Ciprofloxacin Hydrochloride Tablets, USP)
100 mg, 250 mg, 500 mg and 750 mg
ANTIBACTERIAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Quebec
H4P 2T4 DATE OF REVISION: SEPTEMBER 10, 2019
SUBMISSION CONTROL NO.: 229111
_Dom-CIPROFLOXACIN Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
6
WARNINGS AND PRECAUTIONS
............................................................................................
6
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
19
OVERDOSAGE
...........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
21
STORAGE AND STABILITY
....................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................